Corneal Health:
Treating Progressive Keratoconus

Advancing solutions for patients

We’re transforming the standard of care for patients with progressive keratoconus and other corneal ectatic conditions through our commitment to addressing important unmet clinical needs in corneal health.

With inspired innovation, a customer-centric focus, and prolific market access capabilities, we are in the constant pursuit of developing proven solutions in corneal health that empower eye care professionals to deliver optimal care for patients.

Keep keratoconus from calling the shots

iLink™ is the only FDA-approved cross-linking procedure that slows or halts progressive keratoconus to help preserve patients’ vision.

Learn More About iLink™

Find an iLink™ expert near you

Connect with a doctor performing the only FDA-approved cross-linking procedure today.

Get started

The iDetect KC program

Bringing the power of advanced topography into optometrist practices.

Find Out More

Tailor-made market access solutions

Every patient deserves access to procedures that can help preserve their vision. iLink™ corneal cross-linking helps patients avoid sight-threatening disease progression. That’s why the iPath360 program provides strategic and trustworthy market access solutions for all Glaukos procedures and products in glaucoma, corneal health, and retinal disease care.

Explore iLink™ Reimbursement

Using Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution), and the KXL® System, the iLink™ corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery.*1

[Photrexa IFU/p1/col1/para3/lines1-4]

Indications

Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.

Important Safety Information

Corneal collagen cross-linking should not be performed on pregnant women.

Ulcerative keratitis can occur. Patients should be monitored for resolution of epethelial defects. The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision.

These are not all the side effects of the corneal collagen cross-linking treatment. For more information, go www.livingwithkeratoconus.com to obtain the FDA-approved product labeling.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL® System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.

Reference

1. Photrexa [package insert]. Waltham, MA: Glaukos, Inc. 2016